Alnylam Pharmaceuticals Inc banner

Alnylam Pharmaceuticals Inc
SWB:DUL

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
SWB:DUL
Watchlist
Price: 177.65 EUR -28.94%
Market Cap: €14.4B

Wall St Price Targets

DUL Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast DUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DUL is 353.72 EUR with a low forecast of 202.32 EUR and a high forecast of 517.61 EUR.

Lowest Forecast
Price Target
202.32 EUR
14% Upside
Average Forecast
Price Target
353.72 EUR
99% Upside
Highest Forecast
Price Target
517.61 EUR
191% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
RLMD
Relmada Therapeutics Inc
151% Upside
8841
TOC Co Ltd
41% Upside
STRO
Sutro Biopharma Inc
94% Upside
8961
Mori Trust Sogo Reit Inc
10% Upside
AMSF
Amerisafe Inc
25% Upside
CSGP
CoStar Group Inc
26% Upside

Revenue
Forecast

36% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
36% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.

Gross Profit
Forecast

N/A
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

The compound annual growth rate for Gross Profit over the next 8 years is 19%.

Operating Income
Forecast

N/A
Past Growth
37% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
37% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 37%.

Pre-Tax Income
Forecast

N/A
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 3 years is 92%.

Net Income
Forecast

N/A
Past Growth
40% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
40% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate for Net Income over the next 8 years is 40%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is DUL's stock price target?
Price Target
353.72 EUR

According to Wall Street analysts, the average 1-year price target for DUL is 353.72 EUR with a low forecast of 202.32 EUR and a high forecast of 517.61 EUR.

What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.

What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
19%

The compound annual growth rate for Gross Profit over the next 8 years is 19%.

What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
37%

The compound annual growth rate for Operating Income over the next 8 years is 37%.

What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
92%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 92%.

What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
40%

The compound annual growth rate for Net Income over the next 8 years is 40%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett